Featuring Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer.
In a recent episode of the AI in Business Podcast sponsored by AnswerRocket, Vaithi Bharath, Associate Director of Data Science & AI Solutions at Bayer, joined host Matthew DeMello, Editorial Director at Emerj AI Research, to explore one of pharma’s most persistent challenges: decision cycles that should take hours but drag into days or weeks. The conversation reveals how guided, explainable AI workflows can cut days from clinical trial cycles without requiring expensive system replacements or compromising audit readiness.
Vaithi brings deep expertise in navigating the complex intersection of AI innovation and pharmaceutical validation requirements. From electronic data capture systems to final submission deliverables, he explains where time gets lost in the handoffs between EDC, labs, safety databases, CTMS, and statistical computing environments—and how AI-assisted workflows can complement validated systems to reduce delays while actually improving compliance posture.
In This Episode, You’ll Learn:
- (02:15) Where Decision Cycles Stall: The Hidden Cost of System Fragmentation
- (05:30) The Clinical Data Journey: From Site Capture to Submission Deliverables
- (08:45) Concrete Example: When a Simple Integration Change Triggers Months of Workarounds
- (12:20) 21 CFR Part 11: How Validation Changes Everything
- (15:40) What Auditors Actually Look For: Data Integrity, Traceability, and Security
- (18:25) The Future of Pharma Workflows: Guided, Explainable, Human-Approved
- (21:50) AI as Co-Pilot: Reusable Macros and Faster Database Locks
- (25:30) Wrappers Over Rip-and-Replace: Leveraging APIs to Preserve Validated Cores
- (29:15) Starting Small: The Governed Sandbox Approach
- (31:40) Consolidation Trends: From Disparate Systems to Integrated Stacks
Key Insights from Vaithi Bharath:
On Where Time Gets Lost: “From the site to getting to a submission state, there are at least four or five different areas of handover between systems for data. The systems are not always well integrated. This often requires manual file transfers, format conversion, reconciliation—and all of this needs to come together before the drug lifecycle is completed and deliverables are produced.”
On Validation vs. Testing: “Testing is running a function to see that it works. Validation is asserting what must and must not happen. We need to be able to explain the lineage of data—who created the file, what was the timestamp, did somebody touch it, how many records were in the file, was there any corruption. It’s a time-consuming and expensive process, but until that’s done, we have to tolerate inefficient workarounds.”
On AI as Co-Pilot: “This isn’t going to replace analysts. Their knowledge and understanding makes them the coaches, the supervisors. When you have a clear lineage of who touched documents at what point, it saves time for statistical programmers to go back and find out who did what. These things can be facilitated by AI tools to reduce cycle time.”
On Wrappers Over Rip-and-Replace: “You don’t need to rip out existing systems. Technical teams can build wrappers—every AI tool has APIs that can be leveraged to build adapters that leverage data from existing systems and add a layer on top providing these workflows. If you don’t touch the underlying framework itself, you’re not revalidating the framework. You’re just testing this workflow tool, which saves significant time and can be done in parallel.”
On Reusable Validation Macros: “When processes are standardized using guided workflows, teams can build more reusable validation macros. You can increase reusability from maybe 40-50% to 70-80%, which produces significant time reduction. This translates directly into shorter review cycles and faster database locks with fewer amendments.”
Resources and Concepts Mentioned:
- Key Pharma Systems:
- EDC (Electronic Data Capture): Systems like Medidata and Veeva capturing clinical trial data
- SDTM/ADAM: Industry-standard formats for clinical data and analysis
- 21 CFR Part 11: FDA requirements for electronic records and signatures
- Database Lock: Point where clinical trial data becomes final for analysis
- AI Workflow Concepts:
- Guided Workflows: AI-assisted processes with human approval at key decision points
- Data Lineage: Complete traceability from source data to final deliverables
- Wrappers and Adapters: API-based layers connecting to existing systems without replacement
- Reusable Validation Macros: Standardized validation code working across multiple studies
Why This Matters for Life Sciences Leaders:
Vaithi’s insights reveal a fundamental tension in pharmaceutical R&D: the same validation requirements that ensure patient safety and data integrity are creating system delays that stretch timelines and inflate costs. The traditional response—massive system replacement projects—triggers extensive revalidation cycles that can take months or years, forcing teams to tolerate inefficient workarounds in the interim.
The solution isn’t choosing between speed and compliance. AI-guided workflows can actually improve audit posture while cutting cycle time by standardizing routine tasks, creating immutable audit trails, and reducing the manual handoffs where delays accumulate. The key is treating AI as a co-pilot that complements domain expertise rather than replacing it, and building wrappers around validated systems rather than replacing them.
For organizations managing hundreds or thousands of SKUs across global markets, multiple manufacturing facilities, and complex supply chains, the principles Vaithi describes translate directly: standardize the routine, preserve the validated core, and let human experts focus on judgment calls rather than repetitive reconciliation.
Want to Learn More?
Interested in how agentic AI can accelerate decisions in your regulated environment while maintaining compliance? Book a meeting with our team.
Related Resources:
